Kymera Therapeutics, Inc. Income Statement
KYMR / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$39M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$349M
FY2025
Net Income
-$311M
FY2025
Kymera Therapeutics, Inc. reported $39M in revenue and $311M in net loss for FY2025. Revenue has grown at a 54.0% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M | $2.9M | $2.9M | $2.9M |
| Cost of Revenue | $39.2M | $47.1M | $78.6M | $46.8M | - | - | - |
| SG&A Expense | $68.2M | $63.5M | $55.0M | $43.8M | $8.0M | $8.0M | $8.0M |
| R&D Expense | $316.6M | $240.2M | $189.1M | $164.2M | $37.2M | $37.2M | $37.2M |
| Operating Income | -$349.4M | -$261.6M | -$165.5M | -$161.3M | -$42.2M | -$42.2M | -$42.2M |
| Income Tax | $0 | - | - | $0 | $0 | $0 | $0 |
| Net Income | -$311.4M | -$223.9M | -$147.0M | -$154.8M | -$41.2M | -$41.2M | -$41.2M |
| EPS (Basic) | -$2.52 | -$2.87 | -$2.09 | -$3.15 | - | - | - |
| EPS (Diluted) | -$2.52 | -$2.87 | -$2.09 | -$3.15 | -$24.28 | -$24.28 | - |
| Shares Outstanding | 64.9M | 55.6M | 48.0M | 51.5M | 44.5M | 1.9M | 1.7M |
| Operating Margin | -891.1% | -555.8% | -210.6% | -344.4% | -1438.5% | -1438.5% | - |
| Profit Margin | -794.0% | -475.6% | -187.0% | -330.6% | -1405.8% | -1405.8% | - |